



ALK
Investor Relations Department
BÅge Alle 6-8
Horsholm DK-2970
Denmark

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

OMX: ALKB

Last Trade:	723.00
Trade Time:	4:59 PM ET Feb 21, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	646.00 - 1133.00
Volume	N/A

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

ALK is the world leader in allergy vaccination (immunotherapy). It is the goal of ALK to increase the awareness of the company and its activities through a structured, ongoing, timely and balanced dialogue with investors, shareholders and other stakeholders. It is also a company goal to secure the liquidity of the company's shares and to generate reasonable, long-term returns to shareholders through share price increases and dividends.... [\(more\)](#)

Company releases [\[View all \]](#)

Feb 21, 2018
[New medicine for house dust mite allergic rhinitis and allergic asthma now available in France](#)

Feb 16, 2018
[ALK's partner, Torii, gains paediatric approval for the house dust mite SLIT-tablet in Japan](#)

Feb 13, 2018
[Annual General Meeting in ALK-Abelló A/S on 12 March 2018](#)

Feb 6, 2018
[ALK releases its annual report 2017](#)

Jan 30, 2018
[Release date of annual report 2017 and audio cast](#)

Upcoming Events [\[View all \]](#)

Mar 12, 2018
[AGM](#)

Mar 15, 2018
[Carnegie Healthcare Seminar, Stockholm](#)